ADUHELM (Aducanumab)

ADUCANUMAB

MONOCLONAL ANTIBODIES

ANTI-AMYLOID BETA

HIGH AFFINITY HUMANIZED IgG1 MONOCLONAL ANTIBODIES

BINDS TO BETA AMYLOID

DECREASES PLAQUES IN NEURONES

For early ALZHEIMER’S DISEASE

MCI = MILD COGNITIVE IMPAIRMENT

MILD DEMENTIA

🟥Aduhelm inclusion
🔲MCA or mild dementia
🔲MMS 21-30 or
🔲MoCA : 17 to 30
🔲Amyloid positive PET or CSF findings 🔲consistent with Alzheimer’s disease or 
🔲CSF Amyloid positive
🔲Exclude non Alzheimer’s disorders
🔲Stable cardiovascular status
🔲Medically stable
🔲Psychologically stable
🔲Not an anticoagulant
🔲Patients excluded if there are any CNS BLEED
  • SIDE EFFECTS:
  • ARIA-E  edema of brain (35%) – w headache, confusion, nausea vomiting tremors gait disturbances & mental status change
  • ARIA : Amaloid related imaging abnormalities
  • HA 21%
  • ARIA-H microHemorrhage of brain (19%) w headache nausea, vomiting, focal neuro def,  decrease level of consciousness, stiff neck. Seizures. 15% superficial siderosis 
  • 15% Falls 
  • 9% diarrhea
  • 8% confusion, mental status change

Once a month injection in Normal Saline

https://www.fda.gov/media/143504/download

+1
1
+1
0
+1
0
+1
0
+1
0

Leave a Comment